Vir Biotechnology Secures $335 Million Through Astellas Partnership

Key Facts

1The Astellas deal provides Vir Biotechnology with $335 million in upfront and near-term payments plus a premium equity investment.

2The company has fully enrolled its phase 3 program for hepatitis delta virus treatment.

Vir Biotechnology has entered into a partnership deal with Astellas that provides $335 million in upfront and near-term payments. Seeking Alpha reported that the agreement includes a premium equity investment, providing the company with significant non-dilutive capital while validating its PRO-XTEN technology platform. Additionally, the company has fully enrolled its phase 3 clinical program for the treatment of hepatitis delta virus.

VIR closed at $10.51 on September 28, 2026, with the stock trading between a day low of $10.33 and a high of $10.69 during that session. These clinical and financial milestones occur as market expansion by competitors increases the addressable market for Vir Biotechnology’s upcoming trials.